Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer - European Medical Journal

Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses the results of the double-blind, phase 3 PALOMA3 trial of fulvestrant with or without the novel CDK 4/6-inhibitor, palbociclib, in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who progressed on prior endocrine therapy.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>